Piglet cells used to treat Type 1 diabetes

Australia's Living Cell Technologies is garnering headlines with some intriguing responses tracked in a tiny diabetes trial undertaken in Russia. Two volunteers were injected with insulin-producing pancreas cells taken from piglets. With the smallest dose, volunteers demonstrated a 25 percent reduction in their insulin requirements. CEO Dr. Paul Tan called the trial results a "breakthrough" in treating Type 1 diabetes. The key to making it work, says the company, is coating the pancreas cells with a gel that prevents them from being marked for destruction by the human immune system and allows them to express insulin. That coating process prevents the need for using immuno-suppressant therapies.

- see the release on LCT's work
- read the report from The Age

Related Articles:
LCT's stem cell research should be encouraged. Editorial
Diabetes epidemic triggers soaring drug market. Report

Read more on: Type 1 Diabetes

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.